Pharma Marketing Network

SEPTEMBER 19, 2023

Predictive analytics is a powerful tool used across industries to analyze data and make predictions about future trends. Predictive analytics is a form of data mining that uses various methods and techniques to analyze historical data and make predictions about future trends and outcomes.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Patient Care 52

pharmaphorum

OCTOBER 31, 2022

Forecasting is essential in providing clarity on decision making about the future, but poor-quality forecasts can result in decisions which are commercially damaging to organisations. Having good forecast models is critical for effective and efficient decision-making. 2: A good forecast will have no secrets.

Communication 52

Communication Labelling 52

STAT

SEPTEMBER 20, 2023

Northeastern University has been selected for a leading role in a new national network formed to better forecast the spread of a future pandemic. The university  announced  Tuesday the US Centers for Disease Control and Prevention has awarded it $17.5

68

68

European Pharmaceutical Review

MARCH 27, 2023

According to the data, the market is forecasted to increase by $2,487.91 Growth-based rapid microbiological testing The market share growth of the growth-based segment is expected to be significant during the forecast period. percent between 2022 and 2027. The segment was valued at $1,492.53 Charles River Laboratories, Danaher Corp.,

Compounding 106

Compounding Vaccines 106

pharmaphorum

JANUARY 27, 2023

As the legendary investor Warren Buffett once said, forecasts about the future usually tell you more about the forecaster than they do about the future. Still, pretty much every business decision is based on some kind of forecast, or scenario; the alternative would be to do nothing, ever.

Packaging 100

Packaging Vaccines 100

STAT

FEBRUARY 1, 2024

Damian here with the latest twist in biotech’s recovery, a close look at Bluebird Bio, and the uncertain future of a Covid-19 player. Adjusted earnings are forecast to be between $8.44 The company had previously forecast $1 billion in 2023 sales before cutting that number in half. Current Street consensus is $63.5

Vaccines 107

Vaccines Communication Insurance 107

European Pharmaceutical Review

OCTOBER 27, 2023

According to The Biosimilar Medicines Group, part of Medicines for Europe, a new report by IQVIA indicates there is a window of opportunity for the EU to foster future-proof biosimilar competition. This publication has come in wake of the EU actively reviewing its Pharmaceutical Legislation.

94

94

European Pharmaceutical Review

AUGUST 9, 2023

Future of the antibody-drug conjugate therapy market By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion, the research predicted. More investment in research and development is expected in the future, noted GlobalData.

93

93

European Pharmaceutical Review

MAY 10, 2024

Artificial intelligence (AI) could also play a part in the future of the [CGT supply chain], however its application in the sector is not imminent” Scalability is another factor that will define the logistics landscape in 2024 and beyond. “However, it is important to balance scalability with personalised solutions. cited 2024May].

Communication 88

Communication Hospitals 88

pharmaphorum

AUGUST 10, 2020

One of the world’s global biotechnology companies a leader, in innovative scientific research in rare diseases, approached J+D Forecasting with a set of forecasting challenges. J+D Forecasting had worked with the team previously to build better forecast models. PowerPoint slide reporting was time-consuming and repetitive.

52

52

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Coronavirus Disease 2019 (Covid-19) Analyst Consensus Sales Analysis and Forecast, H1 2022 , Comirnaty is the leading prophylactic Covid-19 vaccine and recorded sales of $41.3bn in 2021. Vaccine sales helped Pfizer finish second in the top 20 list, with a 95.2% YoY revenue growth. AbbVie reported a 22.7%

Vaccines 108

Vaccines Documentation Compounding FDA 108

European Pharmaceutical Review

NOVEMBER 6, 2023

million by 2033, according to a report by Future Market Insights. As “the next generation treatment solution”, increasing demand for regenerative medicines in cancer “would positively impact” growth of this market over the forecast period, it was highlighted in the report. percent through the next decade.

Compounding 87

Compounding Vaccines 87

Pharmaceutical Technology

MAY 29, 2023

The global pharmaceutical industry experienced a 27% drop in company filings mentions of future of work in Q1 2023 compared with the previous quarter, with the highest share accounted for by Moderna with 13% year-on-year decrease, according to GlobalData’s analysis of over 419 pharmaceutical company filings. Buy the report here.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2% million by 2029.

Vaccines 52

Vaccines FDA 52

pharmaphorum

NOVEMBER 17, 2022

Leela Barham argues that more transparency at a minimum is required next time around, should a VPAS style of agreement be agreed upon for 2024 onwards, and perhaps even a more radical re-think about how a deal is struck in the future. In reality, growth rates have been both lower and higher than forecasted (Table 2).

98

98

InCrowd

NOVEMBER 17, 2022

Better understand how the adoption experience influences future forecasts. In this report InCrowd set out to: Explore the adoption experience and examine the non-adopter’s usage hesitancy. Assess how adopters and non-adopters can best be supported going forward. Get our latest Instant Insights report to see the results.

52

52

Roots Analysis

FEBRUARY 27, 2024

during the forecast period 2023-2035. Each profile features a brief overview of the company, details related to its financial information, technology portfolio, recent developments and an informed future outlook. The global genome editing market is anticipated to grow at a CAGR of 12.6% Get a complete list of the presentations, here.

40

40

Pharmaceutical Technology

MAY 30, 2023

In an investor call on 19 May, Catalent reduced its annual net revenue forecast by approximately 10% compared to its February predictions. Our financial performance and operational execution have all fallen significantly short of our expectations and our February forecast, and we accept responsibility for disappointing you.”

Vaccines 52

Vaccines FDA 52

The FDA Law Blog

JANUARY 8, 2024

Our feed saw a number of rosy forecasts for mergers and acquisitions in FDA-regulated industries. Moreover, it requires not only an understanding of what the laws say, but how what the government would be expected to do in the future based on the regulatory compliance history. By John W.M.

FDA 69

FDA 69

European Pharmaceutical Review

FEBRUARY 22, 2024

A report by Towards Healthcare has forecasted that the advanced drug delivery market will value $375.86 In summary, looking to the future, the pharmaceutical industry will be defined by key factors such as continual innovation and heightened efficiency, the report anticipated. billion by 2033. Last year, with a size of $234.84

FDA 85

FDA 85

European Pharmaceutical Review

DECEMBER 4, 2023

Additionally, industry collaborations and partnerships for customised excipients are likely to help the market grow in the near future, the report found. According to the research, a key limitation for the market are the high development costs associated with novel excipients.

Pharmaceutical Companies 91

Pharmaceutical Companies Pharmaceutical Companies 91

European Pharmaceutical Review

OCTOBER 10, 2022

million to support its work in development, scale-up and manufacture of RNA therapies and finance the training centre already established at the site, which aims to upskill the future RNA workforce. Upskilling scientists at the RNA Training Academy is fundamental for the industry to realise this forecast. billion in 2028.

Vaccines 94

Vaccines 94

European Pharmaceutical Review

JANUARY 12, 2024

And when we think of MPC intertwining with hybrid modelling, it paints a picture of a future where control and predictability in biomanufacturing reach unprecedented heights. “We Based on our observations, we expect a significant growth in the number of MPC applications due to existing disciplines and emerging trends.”

75

75

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. Genmab AS’s epcoritamab presents as the top European drug launch and only oncological therapy.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

JULY 5, 2023

billion by the year 2033, a report by Future Market Insights has stated. The global clinical research organisation (CRO) market is expected to reach $139.56 Compound annual growth rate (CAGR) for the market is anticipated to reach 8.4 percent between 2023 and 2033.

Compounding 52

Compounding 52

European Pharmaceutical Review

SEPTEMBER 12, 2023

According to the report, while 62 percent of companies forecast that the first fully AI drug discovered and developed therapy will be approved by the FDA within the next five years, 20 percent thought this can be achieved within two years. The CPHI Annual Report 2023 will be available in full on 23 October. Attending CPHI Barcelona 2023?

FDA 98

FDA Pharmaceutical Companies Pharmaceutical Companies 98

Roots Analysis

JANUARY 18, 2024

Driven by the rising adoption of chromatography techniques in drug discovery and other application areas, the chromatography instrumentation and chromatography consumables market is anticipated to witness considerable market growth during the forecast period.

Vaccines 40

Vaccines 40

European Pharmaceutical Review

JANUARY 5, 2023

The future mRNA therapeutic market. A 2022 market report forecasted that mRNA non-vaccine therapeutics are set to generate $2 billion in sales by 2028. The facility also offers potential for the development of vaccines for other respiratory illnesses, such as flu and respiratory syncytial virus (RSV).

Vaccines 59

Vaccines 59

Pharmaceutical Technology

DECEMBER 15, 2022

through 2031, reaching over $800m across the three major markets (3MM: US, Germany, and Japan), according to GlobalData’s recent report: Congenital Fibrinogen Deficiency: Opportunity Assessment and Forecast. The congenital fibrinogen deficiency (CFD) market is expected to grow at a compound annual growth rate (CAGR) of 1.7%

Compounding 52

Compounding 52

Pharmaceutical Technology

FEBRUARY 23, 2023

More people must be aware of this initiative to help improve the survival rate in the future. Bowel cancer is a significant health burden, and GlobalData epidemiologists forecast that there are 47,000 diagnosed incident cases of bowel cancer in the UK in 2023.

52

52

Pharmaceutical Technology

FEBRUARY 3, 2023

According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. billion in 2022.

Compounding 52

Compounding 52

pharmaphorum

JULY 27, 2022

billion) – ahead of forecasts – although costs associated with the separation of consumer health unit Haleon as a separately listed company contributed to a 35% decline in operating profit to £1.1 Total revenues came in at £6.9 billion ($8.3

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MARCH 22, 2023

Of the 37 in clinical trials and 24 in early development, GlobalData forecasts that 27 will receive regulatory approval by 2025. While the current focus lies in the areas of mHealth apps, digital therapeutics (DTx), and IoT, future treatment options could surface from emerging technologies such as the metaverse and robotics.

FDA 52

FDA 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Hence, liver fibrosis is a key criterion that represents the severity of liver illnesses and is an important factor that helps physicians forecast the progression of liver disorders towards cirrhosis. The post The future of diagnosing and monitoring NAFLD/NASH could be noninvasive appeared first on Pharmaceutical Technology.

Compounding 75

Compounding 75

Roots Analysis

AUGUST 7, 2023

Driven by the surge in demand for various types of medical devices and the need for a wide array of medical coatings for these devices, the medical device coating market is anticipated to witness a steady growth during the forecast period.

Adverse Reactions 52

Adverse Reactions 52

pharmaphorum

NOVEMBER 27, 2022

Instead, companies should be looking towards a future where speed and agility are the key components in developing business resilience, rather than a reliance on inventory stockpiles and large quality assured batches. This means batch sizes can be tailored to daily demands rather than market forecasts. About the author.

Communication 105

Communication Pharmaceutical Companies Pharmaceutical Companies Packaging 105

European Pharmaceutical Review

JUNE 15, 2023

According to a report by Future Market Insights, the small molecule innovator contract development and manufacturing organisation (CDMO) market is projected to value $48.09 percent during the forecast period. billion in 2023 and $89.43 billion in 2033.

Compounding 52

Compounding 52